Blog
RSS FeedPosted by Michael Wonder on 14 Apr 2017
U.S. FDA issues complete response letter for baricitinib
14 April 2017 - Eli Lilly and Incyte Corporation announced today that the U.S. FDA has issued a complete response ...
Posted by Michael Wonder on 14 Apr 2017
Fast start for FDA drug approvals in 2017
12 April 2017 - The US FDA is poised to make a comeback from the relatively low number of new ...
Posted by Michael Wonder on 13 Apr 2017
Clinuvel reaches agreement on German Scenesse pricing through AMNOG Arbitration Board
12 April 2017 - Clinuvel today announced that it had reached agreement with the German National Association of Statutory Health ...
Posted by Michael Wonder on 12 Apr 2017
HAS publishes Transparency Commission opinion for Keytruda
12 April 2017 - The opinion relates the use of pembrolizumab by patients with non-small-cell lung cancer. ...
Posted by Michael Wonder on 12 Apr 2017
NICE publishes draft guidance on the use of Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)
12 April 2017 - The Department of Health has asked NICE to produce guidance on using ex vivo expanded autologous human ...
Posted by Michael Wonder on 11 Apr 2017
FDA approves first drug to treat tardive dyskinesia
11 April 2017 - The U.S. FDA today approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the ...
Posted by Michael Wonder on 11 Apr 2017
Scotland gets life-extending ‘crucial’ cancer drug that is TOO EXPENSIVE for England
11 April 2017 - Scottish patients will be able to benefit from a breast cancer drug which could prolong life by ...
Posted by Michael Wonder on 11 Apr 2017
'Gamechanging' cancer drug rejected for use on NHS
11 April 2017 - Nivolumab deemed too expensive for the benefits but cancer specialists urge NHS and manufacturers to reach compromise. ...
Posted by Michael Wonder on 11 Apr 2017
NICE says head and neck cancer drug is not cost effective
11 April 2017 - NICE has published draft guidance saying the cost of using nivolumab to treat head and neck cancer ...
Posted by Michael Wonder on 11 Apr 2017
People at risk of HIV in Scotland to be given PrEP drug on NHS
11 April 2017 - AIDS campaigners say move puts pressure on England to end delays in providing the medication despite two ...
Posted by Michael Wonder on 10 Apr 2017
SMC - April 2017 decisions
10 April 2017 - Medicines for breast cancer, multiple sclerosis and leukaemia among five new treatments accepted for use in ...
Posted by Michael Wonder on 10 Apr 2017
Cancer drug Kadcyla approved for use by NHS Scotland
10 April 2017 - A breast cancer drug which is being withdrawn in England because it is too expensive is ...
Posted by Michael Wonder on 07 Apr 2017
Merck receives complete response letter from the U.S. FDA for TECOS study with sitagliptin
7 April 2017 - Merck today announced that the U.S. FDA has issued a complete response letter regarding Merck’s supplemental new ...
Posted by Michael Wonder on 07 Apr 2017
Institute for Clinical and Economic Review's final report on treatments for rheumatoid arthritis finds evidence inadequate to distinguish overall benefits between newer agents and prices too high in relationship to the clinical value provided to patients
7 April 2017 - Final report and meeting summary reviews evidence on 11 targeted immune modulator drugs, including two currently under ...
Posted by Michael Wonder on 07 Apr 2017
FDA approves two hepatitis C drugs for paediatric patients
7 April 2017 - The U.S. FDA today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to ...